Applied DNA Subsidiary, LineaRx, Inc., Signs Licensing Agreement With LifeSensors, Inc.
Applied DNA Subsidiary, LineaRx, Inc., Signs Licensing Agreement With LifeSensors, Inc.
Press Release: Applied DNA Subsidiary, LineaRx, Inc., Signs Licensing Agreement with LifeSensors, Inc.
新聞稿：應用DNA公司的子公司LineaRx公司與Lifesensors公司簽署許可協議。
Applied DNA Subsidiary, LineaRx, Inc., Signs Licensing Agreement with LifeSensors, Inc.
應用DNA子公司LineaRx公司與Lifesensors公司簽署許可協議。
LineaRx will incorporate LifeSensors' SUMO-fusion technologies to maximize protein expression of PCR-produced Linear DNA
LineaRx將採用Lifesensors的相撲融合技術，最大限度地提高PCR產生的線性DNA的蛋白質表達
STONY BROOK N.Y.--(BUSINESS WIRE)--January 13, 2020--
紐約州石溪--(美國商業新聞網)--2020年1月13日--
Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") announced today that LineaRx, Inc. ("LineaRx"), its majority-owned subsidiary focused on next-generation biotherapeutics and cancer diagnostics, has signed a licensing agreement with LifeSensors, Inc. ("LifeSensors"), to incorporate LifeSensors' high expression SUMO-fusion technologies into the Company's linear DNA amplicons designed and produced for therapeutic applications (the "Agreement"). LifeSensors' SUMO-fusion technologies enable the attachment of the C-terminus of SUMO (Small Ubiquitin Like Modifier) to the N-terminus of a protein of interest that can dramatically improve protein solubility, achieve native protein folding, and increase total yield by improving expression and decreasing degradation.
應用DNA科學公司(納斯達克市場代碼：APDN)(簡稱“應用DNA公司”)今天宣佈，其控股子公司LineaRx，Inc.(以下簡稱LineaRx)已與Lifesensors，Inc.(以下簡稱“Lifesensors”)簽署了一項許可協議，將Lifesensors的高表達相撲融合技術融入該公司為治療應用設計和生產的線性DNA擴增器(以下簡稱Lifesensors)(以下簡稱Lifesensors)：LineaRx，Inc.(簡稱LineaRx)，該公司是LineaRx公司的控股子公司，專注於下一代生物治療和癌症診斷。Lifesensors的相撲融合技術能夠將SUMO(小泛素樣修飾物)的C端連接到目標蛋白質的N端，從而顯著改善蛋白質的溶解性，實現天然蛋白質摺疊，並通過改善表達和減少降解來增加總產量。
Under the terms of the Agreement, LineaRx will have a worldwide license to the applicable LifeSensors intellectual property to make, have made, use, and sell DNA constructs incorporating the SUMO-fusion technologies for therapeutic and diagnostic applications.
根據協議條款，LineaRx將擁有適用的Lifesensors知識產權的全球許可，可以製造、製造、使用和銷售包含相撲融合技術的DNA結構，用於治療和診斷應用。
"We have already demonstrated expression levels for our linear DNA that meets or exceed that of plasmid-produced DNA," stated Dr. James Hayward, president and CEO of Applied DNA. "The incorporation of the SUMO-fusion technologies into our linear amplicons we believe will further optimize protein expression and deliver yet another strength to linear DNA. We are in discussions with therapeutic companies on incorporating the SUMO-fusion technologies into their custom amplicon for the therapy of interest."
應用DNA公司總裁兼首席執行官詹姆斯·海沃德博士説：“我們已經證明，我們的線性DNA的表達水平達到或超過了質粒生產的DNA。”我們相信，將相撲融合技術引入我們的線性擴增器將進一步優化蛋白質的表達，併為線性DNA提供另一種力量。我們正在與治療公司討論將相撲融合技術納入他們定製的擴增子中，用於感興趣的治療。“
"A roadblock to successful gene therapy today is the ability to effectively express and present the therapeutic product in the target cell. Fusion of gene constructs and chimeric genes with SUMOstar overcomes the hurdles of poor gene expression," said Brenda Bausher, Manager of LifeSensors, Inc.
Lifesensors公司經理布倫達·鮑舍爾説：“今天，基因治療成功的一個障礙是在目標細胞中有效表達和呈現治療產品的能力。基因結構和嵌合基因與SUMOstar的融合克服了基因表達不佳的障礙。”
The companies will work together on initially developing and releasing two high expression amplicons; one for the generic Luciferase protein and one for our licensed anti-CD19 therapy.
這兩家公司將合作最初開發和釋放兩種高表達的擴增劑；一種用於通用熒光素酶蛋白，另一種用於我們獲得許可的抗CD19療法。
Data showing the increased expression levels resulting from incorporation of SUMO-fusion technologies are expected to be available over the next few months.
在接下來的幾個月裏，預計將會有數據顯示由於融合相撲技術而增加的基因表達水平。
"This Agreement demonstrates the commitment we have to optimize PCR-produced linear DNA for therapeutic applications. We expect that LifeSensors' proven technology will further strengthen our higher performing alternative to plasmids for nucleic acid-based therapies," concluded Dr. Hayward.
海沃德博士總結説：“這項協議顯示了我們對優化PCR生產的線性DNA用於治療應用的承諾。我們預計，Lifesensors公司經過驗證的技術將進一步加強我們在核酸治療中替代質粒的更高性能。”
About LineaRx, Inc.
關於LineaRx公司
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA's deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction ("PCR"). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.
LineaRx致力於將應用DNA公司在設計、製造和通過大規模聚合酶鏈式反應(“PCR”)對DNA進行化學修飾方面的深厚專業知識和經驗的生物治療價值商業化。線狀DNA是一種不同於通常在質粒中產生並在細菌中生長的環狀DNA的DNA形式。質粒是在細菌中發現的染色體外DNA，與抗生素耐藥性基因相關，這些基因經常在細菌之間交換，因此被許多人認為是對全球健康的嚴重威脅。此外，許多基於核酸的療法也依賴於病毒載體來有效地轉染和表達質粒DNA。這些病毒載體還帶有額外的風險，而且製造起來極其耗時和昂貴。
In all forms of gene therapy, DNA exerts its influence from within the nucleus. Recombinant events for circular DNA are permanent and alter the genomes of the affected cells and their progeny. The fundamental challenge of all gene and cellular therapies is safety. Recent studies have elaborated "unintended consequences" when plasmid and viral vectors are combined that may pose future risks for treated patients.
在所有形式的基因治療中，DNA都是從細胞核內施加影響的。環狀DNA的重組事件是永久性的，會改變受影響細胞及其後代的基因組。所有基因和細胞療法的根本挑戰是安全性。最近的研究已經詳細闡述了當質粒和病毒載體結合時的“意想不到的後果”，這可能會給接受治療的患者帶來未來的風險。
When linear DNA enters the nucleus, it does not need to be incorporated into the genome in to be temporarily expressed as the intended proteins product. LineaRx posits that for the effectiveness of genetic vaccines or genetic immune therapies, transient expression may be sufficient.
當線性DNA進入細胞核時，它不需要被合併到基因組中，就可以暫時表達為預期的蛋白質產物。LineaRx認為，為了基因疫苗或基因免疫療法的有效性，瞬時表達可能就足夠了。
About Applied DNA Sciences, Inc.
關於應用DNA科學公司
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates.
應用DNA公司是一家分子技術供應商，可實現供應鏈安全、防偽和防盜技術、產品基因分型和基於核酸的臨牀前治療藥物候選。
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
應用DNA通過提供創新的、基於分子的技術解決方案和服務，幫助保護公司、政府和消費者的產品、品牌、整個供應鏈和知識產權免受盜竊、假冒、欺詐和挪用，從而使生活變得真實和安全。
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list. Common stock listed on NASDAQ under the symbol APDN.
有關更多信息，請訪問adnas.com。在Twitter和LinkedIn上關注我們。加入我們的郵件列表吧。在納斯達克上市的普通股，代碼是APDN。
About LifeSensors, Inc.
Lifesensors公司簡介
LifeSensors is a biotechnology company focused on SUMO and ubiquitin proteasome and PROTAC drugs, develops and markets technologies for application in protein expression and drug discovery. LifeSensors technologies are employed by academic, government research institutions, pharmaceutical and biotechnology companies worldwide in efforts to improve the quality of human life.
Lifesensors是一家生物技術公司，專注於相撲和泛素蛋白酶體以及PROTAC藥物，開發和營銷應用於蛋白質表達和藥物發現的技術。生命傳感器技術被世界各地的學術、政府研究機構、製藥和生物技術公司用於努力改善人類生活質量。
For more information on our new line of products, please refer to the LifeSensors web site at www.lifesensors.com.
有關我們新系列產品的更多信息，請訪問Lifesensors網站www.lifesensors.com。
Forward-Looking Statements
前瞻性陳述
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the possibility of a failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA's assets, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA's or its partners product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
根據1933年“證券法”第27A條、1934年“證券交易法”第21E條和1995年“私人證券訴訟改革法”的規定，應用DNA公司在本新聞稿中所作的陳述可能具有“前瞻性”性質。前瞻性陳述描述了應用DNA公司的未來計劃、預測、戰略和預期，這些陳述基於假設，涉及許多風險和不確定因素，其中許多風險和不確定因素超出了應用DNA公司的控制範圍。實際結果可能與預期的大不相同，因為可能無法及時支付其未償還的有擔保可轉換票據，並導致票據持有人對抵押品強制執行補救措施，這些抵押品包括Application DNA的幾乎所有資產、其淨虧損的歷史、有限的財務資源、有限的市場接受度、研發中固有的不確定性、未來的臨牀數據和分析，包括是否有Application DNA或其合作伙伴的候選產品將在臨牀前研究或臨牀試驗過程中進一步推進，包括獲得美國食品和藥物管理局(FDA)或同等外國監管機構的批准進行臨牀試驗它們將獲得美國FDA或同等的外國監管機構的最終批准，以及應用DNA在美國證券交易委員會(SEC)不時提交的報告和文件中詳細説明的各種其他因素，包括我們於2019年12月12日提交的Form 10-K年度報告，以及我們提交給SEC的其他報告，這些報告可在www.sec.gov上查閲。除非法律另有要求，否則應用DNA公司沒有義務公開更新任何前瞻性陳述，以反映本新聞稿日期後的新信息、事件或情況，或反映意想不到的事件的發生。
View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005271/en/
在business wire.com上查看源代碼版本：https://www.businesswire.com/news/home/20200113005271/en/
CONTACT: investors: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
聯繫人：投資者：LHA投資者關係部桑傑·M·赫裏(Sanjay M.Hirst)電話：212-838-3777電子郵件：shry@lhai.com
program: Brian Viscount, Applied DNA, 631-240-8877, brian.viscount@adnas.com
項目：應用DNA公司布萊恩·維斯克特(Brian Viscount)電話：631-240-8877電子郵件：brian.viscount@adnas.com
Brenda Bausher, LifeSensors, (610) 644-8845 x 338
布倫達·鮑舍爾(Brenda Bausher)，救生員，(610)644-8845 x 338
web: www.adnas.com
網址：www.adnas.com
twitter: @APDN
推特：@APDN
(END) Dow Jones Newswires
(完)道瓊通訊社
January 13, 2020 09:15 ET (14:15 GMT)
2020年1月13日東部時間09：15(格林尼治標準時間14：15)
*DJ Applied DNA Subsidiary, LineaRx, Inc., Signs Licensing Agreement With LifeSensors, Inc.
*DJ應用DNA子公司LineaRx，Inc.與Lifesensors，Inc.簽署許可協議。
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)
(更多信息)道瓊斯通訊社(212-416-2800)
January 13, 2020 09:17 ET (14:17 GMT)
2020年1月13日東部時間09：17(格林尼治標準時間14：17)
Copyright (c) 2020 Dow Jones & Company, Inc.
版權所有(C)2020道瓊斯公司。
譯文內容由第三人軟體翻譯。